BillionToOne, Inc.
corporate_fare Company Profile
BillionToOne, Inc. (NASDAQ:BLLN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for BLLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for BLLN spans 10-Q, 8-K, 10-K, SCHEDULE 13D.
Recent high-impact activity:
- BillionToOne Rejects Short Seller's Claims, Weighs Legal Action
- Fuzzy Panda Short Report Sends BillionToOne Down 10%
- BillionToOne 10-Q: Q3 Revenue $123.0M, Profit $17.4M, Material Weaknesses Persist
- BillionToOne Beats on Q3 Revenue, Lifts 2026 Outlook to $460-470M
- Peer-Reviewed Study Shows BillionToOne's Tissue-Free Assay Matches or Beats Tumor-Informed Monitoring
Financial Snapshot
Short Interest & Short Volume
6.69 days to coverFINRA reported short interest of 2,970,311 shares in BLLN as of the October 30, 2026 settlement, a 1.3% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 61.8% of BLLN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.